Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home INOmax Program for Severe Cardiopulmonary Diseases
NCT00041574Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Apr 2002
- Primary completion
- Dec 2005
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of nitric oxide in pulmonary hypertension (PH), chronic lung disease, sickle cell disease (SCD), congenital heart disease (CHD), sponsored by Mallinckrodt Pharmaceuticals. Started Apr 2002; status: terminated.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)chronic lung diseasesickle cell disease (SCD)congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT00041574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041574.